Page 245


Please refer to the page image for an unflawed representation of this content.

TABLE F-2 Pharmaceutical Companies: Current (1999) Prospects for Development of New Antituberculosis Drugs and Vaccines

New Antimicrobials Available in:

Company

2 Years

5 Years

8 Years

Vaccines

Abbott Laboratories

0

0

0

0

American Home Products (Lederle/Wyeth-Ayerst)

0

0

0

0

Astro-Zeneca Pharmaceuticals

0

0

0

0

Bristol-Myers Squibb

0

0

0

0

Dupont Pharmaceuticals

0

?oxazolidinones

?oxazolidinones

0

Eli Lilly and Company

0

0

0

0

Glaxo-Wellcome

0

0

?

Working on vaccines

  • DNA

  • Whole attenuated live organism

  • Therapeutic vaccine

Hoechst Marion Roussel

0

0

0

0

Rifapentine approved by FDA in 1998

Janssen Pharmaceuticals

0 0

0 0

Merck and Company

0 0

0

Very exploratory; have rights to a DNA vaccine in the public domain. Would also be interested in a subunit vaccine



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement